series-b
Stage
About
Imcyse is a clinical-stage biopharmaceutical company developing a novel class of specific immunotherapies using synthetic peptides to recalibrate the immune system for the treatment of severe autoimmune diseases such as Type 1 Diabetes and Multiple Sclerosis.
Explore Imcyse's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.